欢迎来到范德生物BIOFOUNT
范德生物中国

中文范德生物中文语言

范德生物产品购买购物车
0
搜索
KAG-308_1215192-68-9_产品详情
1215192-68-9
  • names:

    KAG-308

  • CAS号:

    1215192-68-9

    MDL Number:
  • MF(分子式): C24H30F2N4O3 MW(分子量): 460.52
  • EINECS: Reaxys Number:
  • Pubchem ID: Brand:BIOFOUNT
KAG-308
货品编码 规格 纯度 价格 (¥) 现价(¥) 特价(¥) 库存描述 数量 总计 (¥)
YZM004245-250mg 250mg ¥ 0.00 ¥ 0.00 Backorder
- +
¥ 0.00
YZM004245-100mg 100mg >97% ¥ 0.00 ¥ 0.00 2-3天
- +
¥ 0.00
快速询价
收起
你想询价的产品
请准确填写您的联系方式,以便为您提供最好的服务。
中文别名 KAG-308;KAG 308;KAG308
英文别名 (2Z,3Ar,4R,5R,6aS)-3,3-difluoro-4-[(E,3R,4R)-3-hydroxy-4-(3-methylphenyl)pent-1-enyl]-2-[4-(2H-tetrazol-5-yl)butylidene]-4,5,6,6a-tetrahydro-3aH-cyclopenta[b]furan-5-ol
CAS号 1215192-68-9
Inchi InChI=1S/C24H30F2N4O3/c1-14-6-5-7-16(12-14)15(2)18(31)11-10-17-19(32)13-20-23(17)24(25,26)21(33-20)8-3-4-9-22-27-29-30-28-22/h5-8,10-12,15,17-20,23,31-32H,3-4,9,13H2,1-2H3,(H,27,28,29,30)/b11-10+,21-8-/t15-,17+,18-,19-,20+,23-/m1/s1
InchiKey KSELABKNBIUMGG-YGBAREPYSA-N
分子式 Formula C24H30F2N4O3
分子量 Molecular Weight 460.52
溶解度Solubility
性状 solid; power
储藏条件 Storage conditions 请根据产品建议的存储条件进行存储,Please store the product under the recommended condition sin the description.
KAG-308(CAS:1215192-68-9)实验注意事项:
1.实验前需戴好防护眼镜,穿戴防护服和口罩,佩戴手套,避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生,必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储,并交于专业生物废气物处理公司处理,以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
产品说明 KAG-308 是一种有效的、选择性、可口服的EP4 receptor(一种前列腺素 E2 受体亚型) 激动剂,抑制结肠炎,促进组织粘膜愈合,有效抑制 TNF-α 的产生
IntroductionKAG08 is a potent selective and orally active agonist of EP4 receptor(a prostaglandin E2 receptor subtype), suppresses colitis and promotes histological mucosal healing, potently inhibits TNF production. KAG08 shows aKiand anEC50of 2.57 nM and 17 nM for human EP4 receptor, respectively, more selective over EP1, EP2, EP3 and IP receptor.
Application1
Application2
Application3
KAG-308 是一种有效的、选择性、可口服的EP4 receptor(一种前列腺素 E2 受体亚型) 激动剂,抑制结肠炎,促进组织粘膜愈合,有效抑制 TNF-α 的产生。KAG-308 对人 EP4 受体的Ki值和EC50值分别为 2.57 nM 和 17 nM,对其选择性高于 EP1,EP2,EP3 和 IP 受体。KAG-308 is a potent selective and orally active agonist ofEP4 receptor(a prostaglandin E2 receptor subtype), suppresses colitis and promotes histological mucosal healing, potently inhibits TNF-α production. KAG-308 shows aKiand anEC50of 2.57 nM and 17 nM for human EP4 receptor, respectively, more selective over EP1, EP2, EP3 and IP receptor[1].
警示图
危险性
危险性警示
安全声明
安全防护
备注
【1】.Watanabe Y, et al. KAG-308, a newly-identified EP4-selective agonist shows efficacy for treating ulcerative colitis and can bring about lower risk of colorectal carcinogenesis by oral administration. Eur J Pharmacol. 2015 May 5;754:179-89.
【2】.Nishimura R, Shirasaki T, Tsuchiya K, Miyake Y, Watanabe Y, Hibiya S, WatanabeS, Nakamura T, Watanabe M. Establishment of a system to evaluate the therapeutic effect and the dynamics of an investigational drug on ulcerative colitis using human colonic organoids. J Gastroenterol. 2019 Jan 1. doi: 10.1007/s00535-018-01540-y. [Epub ahead of print] PubMed PMID: 30599053.
【3】.Toyoda Y, Morimoto K, Suno R, Horita S, Yamashita K, Hirata K, Sekiguchi Y, Yasuda S, Shiroishi M, Shimizu T, Urushibata Y, Kajiwara Y, Inazumi T, Hotta Y, Asada H, Nakane T, Shiimura Y, Nakagita T, Tsuge K, Yoshida S, Kuribara T, Hosoya T, Sugimoto Y, Nomura N, Sato M, Hirokawa T, Kinoshita M, Murata T, Takayama K, Yamamoto M, Narumiya S, Iwata S, Kobayashi T. Ligand binding to human prostaglandin E receptor EP(4) at the lipid-bilayer interface. Nat Chem Biol.2019 Jan;15(1):18-26. doi: 10.1038/s41589-018-0131-3. Epub 2018 Dec 3. PubMed PMID: 30510193.
【4】. Watanabe Y, Murata T, Amakawa M, Miyake Y, Handa T, Konishi K, Matsumura Y, Tanaka T, Takeuchi K. KAG-308, a newly-identified EP4-selective agonist shows efficacy for treating ulcerative colitis and can bring about lower risk of colorectal carcinogenesis by oral administration. Eur J Pharmacol. 2015 May 5;754:179-89. doi: 10.1016/j.ejphar.2015.02.021. Epub 2015 Feb 19. PubMed PMID: 25704618.
 
    对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
        新闻
        抱歉,暂无数据!
        My title page contents